Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma
- 1 February 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (3) , 646
Abstract
PURPOSE: To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors. PATIENTS AND METHODS: A total of 80 patients with recurrent glioblastoma multiforme or anaplastic astrocytoma were seen for baseline evaluations before beginning a phase I or phase II clinical trial. Each patient received a battery of nine brief tests measuring cognitive function, ability to perform activities of daily living (ADLs), and quality of life (QOL). Tests were given monthly after treatment was begun. RESULTS: Performance on a test of verbal memory was independently and strongly related to survival after accounting for age, Karnofsky performance status score, histology, and time since diagnosis. Models incorporating three of nine and all nine tests in the battery accounted for significantly more variance in survival than did the clinical variables alone. Measures of QOL and ADLs (bathing, feeding, and so on) were not independently related to survival, although they provide clinical information that is important for patient care. CONCLUSION: These results indicate that a multifaceted assessment of cognition, QOL, and patient function is practical for brain tumor patients in clinical trials and can provide information regarding the relative risks versus benefits of new treatment regimens that supplements the information from the usual clinical variables.Keywords
This publication has 12 references indexed in Scilit:
- Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.Journal of Clinical Oncology, 1998
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998
- Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumorsCancer, 1995
- Cognitive functioning in long-term survivors of high-grade gliomaJournal of Neurosurgery, 1994
- Recording neurological impairment in clinical trials of gliomaJournal of Neuro-Oncology, 1994
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993
- A note on a general definition of the coefficient of determinationBiometrika, 1991
- Prognostic factors for high-grade malignant glioma: Development of a prognostic indexJournal of Neuro-Oncology, 1990
- A note on the generalized information criterion for choice of a modelBiometrika, 1980